The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
Open accessAbstract
BACKGROUND: Recently, a cluster of patients was observed in France in whom primary pulmonary hypertension developed in patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. METHODS: In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age. RESULTS: The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used to a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs. CONCLUSIONS: The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since their use is expected to increase in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary Pulmonary Hypertension
Rich, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., Detre, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,027
Self-citationThe Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,558
Self-citationTreatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 701
Increased plasma serotonin in primary pulmonary hypertension
Hervé, P., Launay, J., Scrobohaci, M.-L., Brenot, F., Simonneau, G., PETITPRETZ, P., Poubeau, P., Cerrina, J., Duroux, P., & Drouet, L. O. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80156-9 · Cited by 557
Self-citationHadengue, A., Benhayoun, M. K., Lebrec, D., & Benhamou, J. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90225-a · Cited by 497
Primary Pulmonary Hypertension and Cirrhosis: Are They Related?
McDonnell, P. J., Toye, P. A., & Hutchins, G. M. (1983) · American Review of Respiratory Disease · doi:10.1164/arrd.1983.127.4.437 · Cited by 318
Primary Pulmonary Hypertension
Rubin, L. J. (1993) · CHEST Journal · doi:10.1378/chest.104.1.236 · Cited by 308
Primary pulmonary hypertension and fenfluramine use.
Brénot, F., Hervé, P., PETITPRETZ, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 247
Self-citationPETITPRETZ, P., Brénot, F., Azarian, R., Parent, F., Rain, B., Hervé, P., & Simonneau, G. (1994) · Circulation · doi:10.1161/01.cir.89.6.2722 · Cited by 238
Self-citationPulmonary hypertension and fenfluramine
Douglas, J. G., Munro, J., KITCHIN, A. H., Muir, A. L., & Proudfoot, A. T. (1981) · BMJ · doi:10.1136/bmj.283.6296.881 · Cited by 180
Research works printed but not linked: 3
- Gurtner HP, 1985, Cor Vasa, 27, 160
- Michelakis ED, 1995, Am J Respir Crit Care Med, 151, A725
- Russel LA, 1992, Am Rev Respir Dis, 145, A717
Cited by
Sorted by citations
Items 801–900 of 999
Pulmonary hypertension: Classification and treatment
Channick, R. N. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)71067-9 · Cited by 4
Saudi guidelines on diagnosis and treatment of pulmonary arterial hypertension
Idrees, M. M., Al-Hajjaj, M. S., Khan, J., Hazmi, M. A., Alanezi, M. O., Saleemi, S., Sanai, F. M., Kashour, T. S., Wali, S., & Barst, R. J. (2008) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.39589 · Cited by 14
Role of iloprost and bosentan in pulmonary arterial hypertension
Saleh, J.-E. A. (2008) · Nigerian Journal of Medicine · doi:10.4314/njm.v17i1.37347 · Cited by 4
Shah, P. M., Freed, M. D., Lytle, B. W., O’Gara, P. T., O’Rourke, R. A., Shanewise, J. S., Nishimura, R. A., Carabello, B. A., Faxon, D. P., Otto, C. M., et al. (2009) · Cited by 4
Munshi, A., Sharma, V., & Sharma, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809411-2.00010-6 · Cited by 4
Benfluorex metabolism complemented by electrochemistry-mass spectrometry
Göldner, V., & Kärst, U. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115626 · Cited by 4
Diseases of Pulmonary Circulation
Lakshminrusimha, S., & Kumar, V. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-07307-3.10048-5 · Cited by 4
Treatment of Childhood and Adolescent Obesity
Alemzadeh, R. (1998) · Endocrine Practice · doi:10.4158/ep.4.6.417 · Cited by 4
O’Brien, A., & Rounds, S. (2000) · Comprehensive Therapy · doi:10.1007/s12019-000-0008-7 · Cited by 4
Pharmacoepidemiology: lessons from real life
Fautrel, B. (2003) · Joint Bone Spine · doi:10.1016/j.jbspin.2003.07.008 · Cited by 4
Uso de moderadores de apetite entre estudantes da área da saúde na Região Sul do Brasil
Zúbaran, C., & Lazzaretti, R. (2013) · Einstein (São Paulo) · doi:10.1590/s1679-45082013000100009 · Cited by 4
Pulmonary hypertension: work in progress
Boyce, P. D., & Waxman, A. B. (2003) · Journal of Nuclear Cardiology · doi:10.1016/s1071-3581(03)00549-x · Cited by 4
Helping an obese patient make informed choices
Mulrow, C. D. (1998) · BMJ · doi:10.1136/bmj.317.7153.266 · Cited by 4
Lynch, M. J., Burns, R. G., & Holcomb, J. E. (2005) · Criminal Justice Review · doi:10.1177/0734016805285177 · Cited by 4
Classification and Prognosis of Pulmonary Arterial Hypertension
Friedman, E. B., Palevsky, H. I., & Taichman, D. B. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-2246-6.50011-0 · Cited by 4
Obesity and pulmonary hypertension
Antkowiak, M., & Channick, R. N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813553-2.00009-9 · Cited by 4
Gratz, I. (1999) · Anesthesiology Clinics of North America · doi:10.1016/s0889-8537(05)70125-5 · Cited by 4
Valodia, P., & Syce, J. A. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001773689 · Cited by 4
Antiobesity drug therapy: a call for more rigorous end-point evaluation
Padwal, R. S. (2007) · Therapy · doi:10.2217/14750708.4.3.221 · Cited by 4
Sclérodermies induites par des médicaments
Fautrel, B., & Bourgeois, P. (2002) · Revue du Rhumatisme · doi:10.1016/s1169-8330(02)00316-2 · Cited by 4
Brain serotonin neurotoxicity and fenfluramine and dexfenfluramine.
O'Callaghan, J. P., & Miller, D. J. S. (1997) · PubMed · Cited by 4
New Approaches to Pulmonary Hypertension
Russo-Magno, P. M., & Hill, N. S. (2001) · Hospital Practice · doi:10.3810/hp.2001.03.231 · Cited by 4
Pulmonary Hypertension, Sleep-Disordered Breathing, and Beta Blockers in Heart Failure Patients
Blankfield, R. P. (2002) · Sleep And Breathing · doi:10.1007/s11325-002-0181-2 · Cited by 4
Historical milestones in the study of pulmonary hypertension
Константиновна, О. А., Rodnenkov, O. V., & Martynyuk, T. V. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.03.203137 · Cited by 3
5-HT2B Receptor on Macrophages: What for?
Nieto, C., Rayo, I., & Corbí, A. L. (2021) · The Receptors · doi:10.1007/978-3-030-55920-5_6 · Cited by 3
Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications
López, J. C., Pare, J. R., Blackmer, A. B., & Orth, L. E. (2022) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2022.05.003 · Cited by 4
Tratamiento de la obesidad infanto-juvenil
Martul, P., Rica, I., Vela, A., & Grau, G. E. (2002) · Anales de Pediatría · Cited by 3
Complicações da aorta pós-cirurgia bariátrica
Gaia, D. F., Palma, J. H., Branco, J. N. R., & Buffolo, Ê. (2008) · Brazilian Journal of Cardiovascular Surgery · doi:10.1590/s0102-76382008000300021 · Cited by 3
Serotonin and feeding regulation
Leslie, M. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813323-1.00013-x · Cited by 3
Davids versus Goliaths: Pharma and academia threats to individual scientists and clinicians
Bennett, C. L., Olivieri, N. F., Hoque, S., Aboulafia, D. M., Ventrone, A., Lubaczewski, C. R., Dong, B. J., Schooley, B. L., Witherspoon, B. J., Ray, P. S., et al. (2022) · The Journal of Scientific Practice and Integrity · doi:10.35122/001c.36564 · Cited by 3
Physiopathologie et traitements de l’hypertension artérielle pulmonaire
Perros, F., Jutant, E., Savale, L., Dorfmüller, P., Humbert, M. J. C., & Montani, D. (2023) · médecine/sciences · doi:10.1051/medsci/2023053 · Cited by 3
Medical disorders in pregnancy : a manual for midwives
Robson, S. C., & Waugh, J. J. S. (2008) · Cited by 3
CARDIOVASCULAR SYSTEMIC LUPUS ERYTHEMATOSUS
Petri, M. (2004) · Elsevier eBooks · doi:10.1016/b9-78-012433-9/01950-034x · Cited by 3
Deuchar, G. A., Hicks, M. N., & MacLean, M. R. (2004) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2004.07.006 · Cited by 3
Sakurai, Y., Tanabe, N., Sekine, A., Nishimura, R., Jujo, T., Kawasaki, T., Sugiura, T., Sakao, S., Kasahara, Y., & Tatsumi, K. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0045 · Cited by 3
YADAV, Y. K. (2002) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(02)80016-8 · Cited by 3
Secondary pulmonary hypertension
Sexton, P., & WILSHER, M. L. (2010) · Respiratory Medicine CME · doi:10.1016/j.rmedc.2010.01.001 · Cited by 3
Classification of Pulmonary Hypertension
Hargett, C. W., & Tapson, V. F. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-075-5_2 · Cited by 3
An Epidemiological Study Of Pulmonary Hypertension In Turkish Adults
Pektaş, M. B., Pektaş, A., Emren, S. V., Aldemir, M., Özkeçeci, G., Kula, S., & DOĞAN, İ. (2015) · Mustafa Kemal Üniversitesi Tıp Dergisi · doi:10.17944/mkutfd.86233 · Cited by 3
Génétique et physiopathologie de l’hypertension artérielle pulmonaire primitive ou secondaire
Adnot, S., & Eddahibi, S. (2003) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)33889-0 · Cited by 3
Gender, Sex Hormones, and Pulmonary Arterial Hypertension
Austin, E. D. (2011) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-10.3.160 · Cited by 3
CORRIN, B., & Nicholson, A. G. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3369-8.00008-2 · Cited by 3
Chin, K., & Channick, R. N. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00058-0 · Cited by 3
Patel, M., Daboul, J., Iftikhar, S., Burmeister, C., Ambati, A., Moukarbel, G., & Assaly, R. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001387 · Cited by 3
Novel and emerging therapeutics for genetic epilepsies
Pejčić, A. V., Јаnkovic, S., Đešević, M., Gojak, R., Lukić, S., Marković, N., & Milosavljević, M. N. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1992275 · Cited by 3
Dexfenfluramine, Fenfluramine, and Phentermine for the Treatment of Morbid Obesity
Torretta, L. K., & Schumann, L. L. (1997) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.1997.tb01261.x · Cited by 3
Hipertensión pulmonar primaria y gestación
Barber, M. A., Eguiluz, I., Plasencia, W., Rodríguez, A., Martínez, A. M., & García, J. A. (2004) · Progresos de Obstetricia y Ginecología · doi:10.1016/s0304-5013(04)75995-6 · Cited by 3
Echocardiographic Assessment of Patients Receiving Long-Term Treatment With Anorexiant Medications
Bowen, R. L., Foreyt, J. P., Poston, W. S. C., Miller, C. C., Hyman, D. J., Pendleton, V. R., Gangopadhyay, S., Haddock, C. K., Goodrick, G. K., & Lehbar, S. (1999) · Endocrine Practice · doi:10.4158/ep.5.1.17 · Cited by 3
Silver Lining to the Cloud over Anorexogen-Related Cardiac Valvulopathy?
Sutton, M. S. J. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00018 · Cited by 3
Aminorex to Fen/Phen: An Epidemic Foretold
Tellier, P. (1999) · Circulation · doi:10.1161/01.cir.100.25.e146 · Cited by 3
Hipertensión pulmonar: criterios actuales de diagnóstico y tratamiento
Barberà, J. A. (2002) · Medicina Clínica · doi:10.1016/s0025-7753(02)72461-5 · Cited by 3
Physician Prescribing of Anorexigenics for Weight Loss in Salt Lake County, Utah
Gay, C., Shane‐McWhorter, L., Williams, K., & Stone, M. B. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.11.967.35267 · Cited by 3
Appetite-Suppressant Drugs and Valvular Heart Disease
Williamson, D. F., & Yanovski, S. Z. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400613 · Cited by 3
de Swiet, M. (2002) · doi:10.1002/9780470752371.ch5 · Cited by 3
Engman, M. L., & Richie, R. C. (2000) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-14499-0_23 · Cited by 3
Hypertension artérielle pulmonaire
Montani, D., Yaici, A., Jaïs, X., Sztrymf, B., Cabrol, S., Hamid, A., Parent, F., Sitbon, O., Dartevelle, P., Simonneau, G., et al. (2006) · Encyclopédie médico-chirurgicale. Pneumologie · doi:10.1016/s1155-195x(06)43390-9 · Cited by 3
Self-citationSeaton, T. B., Mendel, C. M., & Weinstein, S. P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801013380114 · Cited by 3
Treatment Response and Survival in Methamphetamine‐Associated Pulmonary Arterial Hypertension
Uhland, C., Gibbs, A., Insel, M. B., Kubba, S., & Rischard, F. P. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042673 · Cited by 2
The Obesity Drug Revolution: New Frontiers in Pharmacotherapy
Manoria, P. C. (2025) · Cureus · doi:10.7759/cureus.96713 · Cited by 2
Anorexigènes et maladies cardiovasculaires : les liaisons dangereuses
Yerly, P., & Vachiéry, J. (2011) · Réanimation · doi:10.1007/s13546-011-0301-8 · Cited by 2
Graham, M. (2008) · Springer eBooks · doi:10.1007/978-0-387-68792-6_31 · Cited by 2
Pulmonary hypertension and metabolic disorders
Shchelkova, G. V., Yarovoy, S. Y., Олеговна, Д. Е., & Chazova, I. E. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-1-37-46 · Cited by 2
Becerra‐Muñoz, V. M., Gómez, J.-T., & Subías, P. E. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.12.014 · Cited by 2
Drug-induced pulmonary artery hypertension
Ostroumova, O. D., Листратов, А. И., Кочетков, А. И., Bliznyuk, S. А., Komarovа, A. G., & Sychev, D. A. (2022) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2022-1-53-63 · Cited by 2
Remillard, C. V., & Yuan, J. X. ‐. (2008) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s696 · Cited by 2
Guignabert, C. (2011) · InTech eBooks · doi:10.5772/26451 · Cited by 2
Setola, V. (2005) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 2
Ross, C. A. (2007) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2007.04.001 · Cited by 2
Exploration d’une hypertension pulmonaire
Natali, D., Simonneau, G., Humbert, M. J. C., & Montani, D. (2008) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2008.05.001 · Cited by 2
Self-citationWillemen, M. J. C., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Leufkens, H. G. M., & Egberts, T. C. G. (2008) · Obesity · doi:10.1038/oby.2008.362 · Cited by 2
Treatment of pulmonary hypertension: A promising new age
Park, M., Scott, R. L., Uber, P. A., & Mehra, M. R. (2002) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.10272 · Cited by 2
The Role of Serotonin in Eating Behavior: Focus on 5-HT2C Receptors
Halford, J. C. G. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-941-3_17 · Cited by 2
MMPs, inflammation and pulmonary arterial hypertension
d’Ortho, M. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8585-9_6 · Cited by 2
Pulmonary arterial hypertension--the primary pulmonary hypertension syndromes.
Hey, J. C., & Scharf, S. M. (2003) · PubMed · Cited by 2
Adverse Drug Reactions in the ICU
Moore, P. W., & Burkhart, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-20790-2_33-1 · Cited by 2
von Willebrand disease: a laboratory approach.
Trasi, S., Ghosh, K., Shetty, S., & Mohanty, D. (2005) · PubMed · Cited by 2
Genetics of Pulmonary Arterial Hypertension
Elliott, C. G. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-2246-6.50010-9 · Cited by 2
Pharmacologic Treatment of Heart Disease
Tanel, R. E., & Levin, M. D. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-02367-2.50020-1 · Cited by 2
Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review.
Leung, Y. Y., Tang, K. S., Tsang, C. C., Chan, C. K., Wong, K. K., & Yu, A. W. (2006) · PubMed Central · Cited by 2
Channick, R. N., & Rubin, L. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00052-3 · Cited by 2
Sharma, S., Chaudhary, M., Sharma, D., & Rani, A. (2023) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.57.3s.81 · Cited by 2
Pharmacologic management of obesity
Tsai, L. W. (1998) · Primary Care Update for OB/GYNS · doi:10.1016/s1068-607x(98)00003-1 · Cited by 2
Goodrick, G. K., Poston, W. S. C., & Foreyt, J. P. (1997) · Eating Disorders · doi:10.1080/10640269708249241 · Cited by 2
European withdrawal of appetite suppressants
Kinnell, H. G. (2003) · Obesity Reviews · doi:10.1046/j.1467-789x.2003.00096.x · Cited by 2
La pharmaco-épidémiologie: une autre surveillance du médicament
Pariente, A. (2015) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30971-9 · Cited by 2
Bishop, A. (1998) · International Journal of Health Promotion and Education · doi:10.1080/14635240.1998.10806077 · Cited by 2
Obese Patients with Binge-Eating Disorder
Marcus, M. D. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-694-2_11 · Cited by 2
Safety and Efficacy of Ambrisentan in the Treatment of Pulmonary Arterial Hypertension
Valerio, C. J., Kabunga, P., & Coghlan, G. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2675 · Cited by 2
Serotoninergic and Mixed Agents
Barceloux, D. G. (2012) · doi:10.1002/9781118105955.ch14 · Cited by 2
PITUITARY‐ADRENAL RESPONSES TO COMBINED ORAL D‐FENFLURAMINE AND INTRAVENOUS NALOXONE IN HUMANS
Grice, J. E., Torpy, D. J., Hockings, G. I., Walters, M. M., Crosbie, G. V., & Jackson, R. V. (1998) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1998.tb02263.x · Cited by 2
Blankfield, R. P. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.167.1.370 · Cited by 2
The evolving epidemiology of pulmonary arterial hypertension
Gomberg‐Maitland, M., & Gaine, S. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01995.x · Cited by 2
Amfepramone does not cause primary pulmonary hypertension
Sacco, G. D. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00119304 · Cited by 2
Sequencing of cognitive‐behavioral treatments for bulimia nervosa
Davis, R., McVey, G. L., Heinmaa, M., Rockert, W., & Kennedy, S. H. (1999) · International Journal of Eating Disorders · doi:10.1002/(sici)1098-108x(199905)25:4 · Cited by 59
Hypertensions artérielles pulmonaires précapillaires
Weitzenblum, E., & Chaouat, A. (2006) · EMC - Cardiologie · doi:10.1016/s1166-4568(02)00073-6 · Cited by 2
Primary pulmonary hypertension: new reasons for optimism?
Williams, T. J. (1998) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb138956.x · Cited by 2
Proietto, J. (1998) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb138997.x · Cited by 2
The etiology and pathogenesis of pulmonary arterial hypertension
Widimsky, J., Jr. (2006) · Cor et Vasa · doi:10.33678/cor.2006.036 · Cited by 2
Defining the Role and Clinical Relevance of BMPR2 Mutations In Pulmonary Arterial Hypertension
Morse, J. H. (2005) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-4.1.5 · Cited by 2
Lorcaserin Safety in Overweight or Obese Patients
Coomes, E. A., Haghbayan, H., & Zipursky, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813971 · Cited by 2
Metadata
- Authors
- Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., & Bégaud, B.
- Affiliations
- Jewish General Hospital (CA)
- Hôpital Antoine-Béclère (FR)
- University of Illinois Chicago (US)
- Centre Hospitalier Universitaire de Liège (BE)
- University of Sheffield (GB)
- Hammersmith Hospital (GB)
- Maastricht University Medical Centre (NL)
- Hôpital Bichat-Claude-Bernard (FR)
- Hôpital Pellegrin (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1996-08-29
- Volume
- 335
- Issue
- 9
- Pages
- 609-616
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2329065056
- Cited by
- 1,162
- References
- 26
- Citations by year
- 2026: 7 · 2025: 23 · 2024: 22 · 2023: 21 · 2022: 22 · 2021: 16 · 2020: 16 · 2019: 20 · 2018: 27 · 2017: 29 · 2016: 18 · 2015: 30 · 2014: 27 · 2013: 39 · 2012: 34
- FWCI
- 71.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- idiopathic pulmonary arterial hypertension, appetite suppressants, drug-induced pulmonary hypertension, risk factors, HIV infection, liver cirrhosis, cocaine use, intravenous drug use, weight management
- MeSH terms
- Adolescent, Adult, Aged, Appetite Depressants, Belgium, Female, Fenfluramine, France, United Kingdom, Heart Function Tests, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Netherlands, Prospective Studies, Respiratory Function Tests, Risk Factors, Incidence, Logistic Models, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
